Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corporation filed a notice of proposed sale of 8,906 shares of common stock through UBS Financial Services Inc. The shares relate to multiple RSU vesting events in 2025, and the filing lists an aggregate market value of $1,121,700.88 for these securities as of the filing details. The shares are listed on the NYSE and the proposed sale date is August 10, 2026.
Encompass Health Corporation insider Douglas Coltharp filed to potentially sell 18,869 shares of common stock through UBS Financial Services Inc. The proposed sale, tied to RSA vesting events dated January and February 2025, has an aggregate market value of $2,365,700.88. Encompass Health reports 98,653,384 shares of common stock outstanding, listed on the NYSE. Over the past three months, Coltharp previously sold 27,694 shares of common stock on May 15, 2026 for $2,958,629.
Encompass Health Corporation reported higher Q2 2026 results, with net operating revenues of $1,597.4 million versus $1,457.7 million a year earlier, driven by 5.6% discharge growth and a 3.9% increase in net patient revenue per discharge. Net income attributable to Encompass Health was $153.9 million, and diluted EPS from continuing operations was $1.55.
For the first half of 2026, net operating revenues reached $3,184.0 million and operating cash flow was $595.7 million. The company operated 176 inpatient rehabilitation hospitals, with occupancy of 77.4% and declining labor intensity as salaries and benefits fell to 51.4% of revenues. Total assets were $7,457.5 million and long-term debt, including current portion, was $2,634.0 million after issuing $500 million of 5.875% 2034 notes and redeeming $400 million of 2028 notes.
Encompass Health Corporation reported higher results for Q2 2026, with net operating revenues of $1,597.4 million, up 9.6% from Q2 2025. Diluted earnings per share from continuing operations were $1.55 compared with $1.40, and Adjusted EBITDA rose 9.2% to $348.0 million. Discharges increased 5.6% to 68,895, driven by 2.8% same‑store discharge growth and a 3.9% rise in net patient revenue per discharge to $22,521.
For the first six months of 2026, net operating revenues reached $3,184.0 million and net income attributable to Encompass Health was $348.4 million, with diluted EPS from continuing operations of $3.32. Management raised full‑year 2026 guidance, projecting net operating revenue of $6,410 to $6,490 million, Adjusted EBITDA of $1,365 to $1,395 million, and adjusted earnings per share of $6.02 to $6.25. Results and outlook are presented using several non‑GAAP measures such as Adjusted EBITDA, adjusted EPS, leverage ratio, and adjusted free cash flow, each reconciled to GAAP metrics.
Liquidity included net cash provided by operating activities of $282.6 million in Q2 and $595.7 million year‑to‑date, while adjusted free cash flow totaled $177.0 million for Q2. The board increased aggregate common stock repurchase authorization to $1 billion; the company had repurchased $145.8 million of common stock year to date and reported cash and cash equivalents of $107.7 million at June 30, 2026.
Vanguard Portfolio Management LLC, together with certain affiliates, reports updated beneficial ownership of Encompass Health Corp common stock on a Schedule 13G/A. The group reports beneficial ownership of 4,935,748 shares, representing 4.97% of the outstanding common stock.
The filer has sole voting power over 11,084 shares and sole dispositive power over 4,935,748 shares, with no shared voting or dispositive power. The filing notes that these holdings include securities held by Vanguard funds and other managed accounts for which Vanguard entities exercise voting and/or dispositive power, and that no other individual person’s interest exceeds 5% of the class.
Encompass Health director Christopher R. Reidy acquired equity through routine compensation-related awards. On July 16, 2026 he received 319 restricted stock units tied to a $0.19 dividend and a $109.88 closing price, and on July 15, 2026 he acquired 21 shares via the Directors Deferred Stock Investment Plan, bringing his direct holdings to 17,777 common shares.
Encompass Health Corp director Edward M. Christie III acquired 248 shares of Encompass Health common stock on July 16, 2026 at a weighted average price of $112.43 per share, plus 11 additional shares on July 15, 2026 from dividend-related awards and director fee deferrals, for a total of 259 shares and direct holdings of 9,345 shares.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received an automatic grant of 29 restricted stock units (RSUs) on July 15, 2026. The RSUs were credited as a dividend equivalent on existing awards, tied to a $0.19 per share common dividend and a $109.88 closing stock price, increasing his direct holdings to 16,859 shares.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an automatic award of 40 restricted stock units tied to Encompass Health common stock on July 15, 2026. The award represents dividend equivalents on existing RSUs, based on a $0.19 per-share dividend and a $109.88 closing price. Following this award, her directly reported holdings total 22,972 shares.
Encompass Health Corp director Kevin J. O'Connor reported an automatic grant/award acquisition of 19 Encompass Health Common Stock-equivalent RSUs on July 15, 2026, at $0.00 per share. These RSUs were credited under existing restricted stock unit agreements in connection with a $0.19 per-share dividend, when the stock closed at $109.88. Following this award, O'Connor directly holds 11,582 shares.